Welcome to our dedicated page for NewAmsterdam Pha SEC filings (Ticker: namsw), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewAmsterdam Pha's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewAmsterdam Pha's regulatory disclosures and financial reporting.
Form 4 filed for James N. Topper, Director of NewAmsterdam Pharma Co. N.V. (NAMSW). The filing reports a securities transaction dated 08/11/2025 and the reporter's related indirect holdings.
On 08/11/2025 the Form 4 shows a transaction with code P reporting the acquisition of 471 ordinary shares at a weighted average price of $23.9787. The filing also discloses indirect holdings of 3,026,604 shares held by Frazier Life Sciences X, L.P. and 3,801,000 shares held by Frazier Lifesciences Sponsor LLC. Footnotes state the purchased shares were bought at prices ranging from $23.91 to $24.00 and include disclaimers that the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest. The form is signed by an attorney-in-fact dated 08/13/2025.
Schedule 13G/A filed for NewAmsterdam Pharma Company N.V. Capital World Investors reports beneficial ownership of 8,387,725 shares, equal to 7.5% of the 112,270,677 shares believed outstanding. The filing states CWI is a division of Capital Research and Management Company and related investment management entities and that these shares are held in the ordinary course of business and not to influence control of the issuer.
The statement shows CWI has sole voting and sole dispositive power over all 8,387,725 shares. The issuer is NewAmsterdam Pharma Company N.V., and CWI's principal business address is 333 South Hope Street, Los Angeles, California. The filing identifies CWI as organized in Delaware.
Forbion-affiliated reporting persons disclosed coordinated holdings in NewAmsterdam Pharma ordinary shares. The combined entity ForGrowth NAP B.V. beneficially owns 10,578,806 Ordinary Shares, representing approximately 9.4% of the outstanding class based on the Issuer's reported share count of 112,628,458. Ownership is reported as shared voting and shared dispositive power for the relevant Forbion entities, while each reporting person reports 0 shares of sole voting or dispositive power. The filing amends prior Schedule 13D disclosures and identifies the allocation of 9,926,633 shares as attributable to Forbion Growth I and Forbion IV through ForGrowth's interest in PoolCo.
This disclosure provides transparency on the size and structure of Forbion's minority stake and the distribution of power among affiliated funds and managers.
NewAmsterdam Pharma (NAMS/NAMSW) furnished an 8-K to disclose full Alzheimer’s disease (AD) biomarker data from the prespecified analysis of its Phase 3 BROADWAY LDL-C trial evaluating CETP inhibitor obicetrapib. In 1,727 patients (367 ApoE4 carriers) treated 12 months with 10 mg daily, obicetrapib produced a -2.99 % mean change in plasma p-tau217 vs. placebo (p = 0.019); effects intensified in genetic and age subgroups, reaching -20.48 % in ApoE4/E4 carriers (n = 29; p = 0.010). Statistically significant or favorable trends were also observed for NFL, GFAP, p-tau181 and Aβ42/40, biomarkers linked to neurodegeneration.
Safety was not analyzed separately but was stated to mirror the overall BROADWAY population, where obicetrapib was well-tolerated and comparable to placebo. The exploratory AD analysis was not adjusted for baseline differences. Results will be presented 30 July 2025 at AAIC; a company webcast will follow at 10:00 a.m. ET. Exhibits 99.1 (press release) and 99.2 (presentation) are furnished, with no financial statements included.
Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma, reported significant insider transactions on June 16, 2025:
- Exercised stock options to acquire 100,000 total ordinary shares: - 78,101 shares at $10.00 per share - 21,899 shares at $10.90 per share
- Subsequently sold 100,000 shares in two tranches: - 81,891 shares at weighted average price of $19.19 - 18,109 shares at weighted average price of $19.75
- Post-transactions, Kling retains: - 44,000 ordinary shares - 372,829 options at $10.00 strike price - 261,314 options at $10.90 strike price
The transactions were executed under a Rule 10b5-1 trading plan. The sales represent a partial liquidation of Kling's holdings while maintaining significant equity exposure through remaining shares and options.